Allogene Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALLO Nasdaq 8731 http://www.allogene.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allogene Therapeutics Inc

We're Not Very Worried About Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Rate - Jun 20th, 2022 7:59 pm
Allogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last? - Jun 20th, 2022 1:28 pm
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma - Jun 8th, 2022 12:30 pm
Why Is Allogene Therapeutics (ALLO) Down 14.9% Since Last Earnings Report? - Jun 3rd, 2022 3:32 pm
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - May 19th, 2022 12:30 pm
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal - May 9th, 2022 12:30 pm
Allogene (ALLO) Q1 Earnings Beat, Pipeline Progresses Well - May 5th, 2022 6:46 pm
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates - May 4th, 2022 9:15 pm
Allogene Therapeutics Reports First Quarter 2022 Financial Results - May 4th, 2022 8:02 pm
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer - Apr 28th, 2022 12:30 pm
Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022 - Apr 27th, 2022 12:30 pm
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma - Apr 27th, 2022 12:00 pm
Aiming to make cell therapy universal, biotech opens East Bay manufacturing center - Apr 14th, 2022 10:00 pm
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products - Apr 14th, 2022 12:00 pm
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal - Apr 13th, 2022 1:00 pm
Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences - Apr 12th, 2022 12:30 pm
Why Is Allogene Therapeutics (ALLO) Up 7.4% Since Last Earnings Report? - Mar 25th, 2022 3:30 pm
Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity - Mar 23rd, 2022 2:12 pm
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma - Mar 23rd, 2022 12:30 pm
Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock? - Mar 21st, 2022 12:10 pm